AtriCure, Inc. provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery. It also provides SUBTLE cannula, an access device and conduit for the ablation device and endoscope to enable a closed chest endoscopic approach; multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable physicians to create an expanded cardiac ablation lesion set. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; and CryoICE CRYO2 cryoablation system to apply cryo-energy to targeted intercostal peripheral nerves in the ribcage and temporarily relieve pain. Further, it provides Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; Fusion Magnetic Retriever System that allows access around anatomical structures; and cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. AtriCure sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:ATRC
CUSIP04963C20
Phone513-755-4100
Debt
Debt-to-Equity Ratio0.32
Current Ratio3.16
Quick Ratio2.37
Price-To-Earnings
Trailing P/E Ratio-37.04
Forward P/E Ratio-33.39
P/E GrowthN/A
Sales & Book Value
Annual Sales$174.72 million
Price / Sales6.22
Cash FlowN/A
Price / CashN/A
Book Value$4.67 per share
Price / Book6.58
Profitability
EPS (Most Recent Fiscal Year)($0.83)
Net Income$-26,890,000.00
Net Margins-10.85%
Return on Equity-16.57%
Return on Assets-9.74%
Miscellaneous
Employees570
Outstanding Shares35,360,000
Market Cap$1.10 billion
AtriCure (NASDAQ:ATRC) Frequently Asked Questions
What is AtriCure's stock symbol?
AtriCure trades on the NASDAQ under the ticker symbol "ATRC."
How were AtriCure's earnings last quarter?
AtriCure Inc. (NASDAQ:ATRC) issued its quarterly earnings data on Wednesday, August, 1st. The medical device company reported ($0.19) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.23) by $0.04. The medical device company earned $51.80 million during the quarter, compared to analysts' expectations of $49.94 million. AtriCure had a negative return on equity of 16.57% and a negative net margin of 10.85%. The firm's revenue for the quarter was up 14.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.21) earnings per share. View AtriCure's Earnings History.
When is AtriCure's next earnings date?
What price target have analysts set for ATRC?
5 brokerages have issued 12 month target prices for AtriCure's stock. Their forecasts range from $30.00 to $37.00. On average, they expect AtriCure's stock price to reach $34.25 in the next year. This suggests a possible upside of 11.5% from the stock's current price. View Analyst Price Targets for AtriCure.
What is the consensus analysts' recommendation for AtriCure?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AtriCure.
What are Wall Street analysts saying about AtriCure stock?
Here are some recent quotes from research analysts about AtriCure stock:
- 1. According to Zacks Investment Research, "AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a quivering of the upper chambers of the heart. " (8/6/2018)
- 2. BTIG Research analysts commented, "In Q2, AtriCure reported $51.8M in revenue, ~3% better than our Street- high forecast." (8/2/2018)
- 3. Needham & Company LLC analysts commented, "ATRC’s 2Q18 revenue accelerated to 13.5% vs. 12.0% in 1Q18 and beat consensus. Management raised its 2018 revenue guidance to $193-197M from $190-196M vs. consensus of $195M and, while management reiterated positive adjusted EBITDA guidance, they noted that elevated legal expenses associated with the DOJ investigation continue to pose a threat to achieving this target. We believe the recent society guidelines, new products (AtriClip Pro-V and Flex-V), and surgeon training activities should drive strong growth. With ATRC shares trading at a ~4 turn discount to peers (2018E EV/sales of 5.3x vs. small/mid-cap growth peers at a median of 9.5x), we reiterate our Buy rating." (8/2/2018)
Who are some of AtriCure's key competitors?
Some companies that are related to AtriCure include Penumbra (PEN), Cantel Medical (CMD), Novocure (NVCR), NuVasive (NUVA), Merit Medical Systems (MMSI), Irhythm Technologies (IRTC), Nevro (NVRO), Tandem Diabetes Care (TNDM), Glaukos (GKOS), Mazor Robotics (MZOR), Cardiovascular Systems (CSII), Luminex (LMNX), Cryolife (CRY), Atrion (ATRI) and Tactile Systems Technology (TCMD).
Who are AtriCure's key executives?
AtriCure's management team includes the folowing people:
- Mr. Michael H. Carrel, CEO, Pres & Director (Age 47)
- Mr. M. Andrew Wade CPA, Sr. VP & CFO (Age 43)
- Mr. Douglas J. Seith, Chief Operating Officer (Age 52)
- Mr. Salvatore Privitera, Chief Technology Officer (Age 51)
- Mr. Justin J. Noznesky, Sr. VP of Marketing & Bus. Devel. (Age 40)
Has AtriCure been receiving favorable news coverage?
News stories about ATRC stock have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. AtriCure earned a daily sentiment score of 0.21 on Accern's scale. They also assigned headlines about the medical device company an impact score of 47.40 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View Recent Headlines for AtriCure.
Who are AtriCure's major shareholders?
AtriCure's stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (14.86%), BlackRock Inc. (7.88%), First Light Asset Management LLC (3.90%), Peregrine Capital Management LLC (2.56%), Emerald Advisers Inc. PA (1.42%) and Cortina Asset Management LLC (1.18%). Company insiders that own AtriCure stock include Andrew L Lux, B Kristine Johnson, Elizabeth D Krell, Justin J Noznesky, M Andrew Wade, Mark A Collar and Regina E Groves. View Institutional Ownership Trends for AtriCure.
Which major investors are selling AtriCure stock?
ATRC stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Peregrine Capital Management LLC, DAFNA Capital Management LLC, Bank of America Corp DE, Wasatch Advisors Inc., Macquarie Group Ltd., Cortina Asset Management LLC and Emerald Advisers Inc. PA. Company insiders that have sold AtriCure company stock in the last year include Elizabeth D Krell, Justin J Noznesky, M Andrew Wade and Mark A Collar. View Insider Buying and Selling for AtriCure.
Which major investors are buying AtriCure stock?
ATRC stock was purchased by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, BlackRock Inc., EAM Investors LLC, FMR LLC, EAM Global Investors LLC, Paradigm Capital Management Inc. NY, Bank of New York Mellon Corp and Bank of Montreal Can. Company insiders that have bought AtriCure stock in the last two years include B Kristine Johnson and Regina E Groves. View Insider Buying and Selling for AtriCure.
How do I buy shares of AtriCure?
Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AtriCure's stock price today?
One share of ATRC stock can currently be purchased for approximately $30.72.
How big of a company is AtriCure?
AtriCure has a market capitalization of $1.10 billion and generates $174.72 million in revenue each year. The medical device company earns $-26,890,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. AtriCure employs 570 workers across the globe.
How can I contact AtriCure?
AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at 513-755-4100.
MarketBeat Community Rating for AtriCure (NASDAQ ATRC)
MarketBeat's community ratings are surveys of what our community members think about AtriCure and other stocks. Vote "Outperform" if you believe ATRC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRC will underperform the S&P 500 over the long term. You may vote once every thirty days.
